US-based global medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Friday that it has received approval from Pharmaceuticals and Medical Device Agency (PMDA) in Japan for the FARAPULSE Pulsed Field Ablation (PFA) System.
The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), and is a novel alternative to standard-of-care thermal ablation treatment.
Boston Scientific is expected to commence the OPTION-A clinical trial in Japan, China, Taiwan and Hong Kong in early 2025. The trial is to study the safety and efficacy of concomitant procedures utilising the FARAPULSE PFA System for cardiac ablation and the WATCHMAN FLX Pro Left Atrial Appendage Closure Device.
The company plans to launch the FARAPULSE PFA System in Japan in the coming weeks, following reimbursement approval.
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
BioCardia secures Japanese patent for Helix biotherapeutic delivery system
Doer Bio completes DR10624phase two clinical study enrolment
Kancera and Recardio sign letter of intent for licensing agreement
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Hims & Hers acquires Trybe Labs to expand at-home testing capabilities
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
BrainCool secures market approval for BrainCool System in Malaysia
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval